Pharmaceuticals News and Research

RSS

Long lasting flu vaccine using antibodies advance from TSRI and Janssen

Scientists from The Scripps Research Institute (TSRI) and the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) have found a way to induce antibodies to fight a wide range of influenza subtypes—work that could one day eliminate the need for repeated seasonal flu shots.

26 Aug 2015

UH research points to promising target in treatment of pancreatic cancer

Pancreatic cancer is extremely deadly and often has a poor prognosis. Ranked as the fourth deadliest cancer in the U.S. and poised to move up within the next few years, pancreatic cancer is very difficult to detect in its early stages. Seldom diagnosed early and typically spreading rapidly, the disease has no effective treatment once it advances.

26 Aug 2015

Clementia expands enrollment to include children with FOP in ongoing Phase 2 clinical trial

Clementia Pharmaceuticals, Inc. today announced the initiation of enrollment of children as young as 6 years old in the company's ongoing Phase 2 study of palovarotene for the treatment of fibrodysplasia ossificans progressiva (FOP).

26 Aug 2015

Lannett's net sales rise 23% to $99.3 million in fourth quarter fiscal 2015

Lannett Company, Inc. today reported financial results for its fiscal 2015 fourth quarter and full year ended June 30, 2015. On June 1, 2015, the company completed the acquisition of Silarx Pharmaceuticals, Inc. The financial results presented below include approximately one month of operations for Silarx, which were not material.

26 Aug 2015

MNX Global Logistics' new Life Sciences Logistics Centre opens in Amsterdam

MNX Global Logistics announces the opening of its dedicated supply chain and logistics facility in Amsterdam, the Netherlands, located just outside of Amsterdam Airport Schiphol. This facility with validated temperature-controlled supply chain capabilities will serve as the operations and warehousing hub for our Life Sciences and Medical Device customers throughout Europe.

25 Aug 2015

Inovalon signs definitive agreement to acquire Avalere Health

Inovalon, a leading technology company providing advanced, cloud-based data analytics and data-driven intervention platforms to the healthcare industry, has entered into a definitive agreement to acquire Avalere Health, Inc., a leading provider of data-driven advisory services and business intelligence solutions to the pharmaceutical and life sciences industry.

25 Aug 2015

Accutest makes strategic expansion into Latin America to support the growth of pharmaceutical sector

Accutest Research Laboratories, a leading global Contract Research Organization (CRO), further pursues its strategic expansion into Latin America by opening offices and establishing operational presence in Brazil.

25 Aug 2015

TSRI, Janssen collaborate to find universal flu vaccine

Scientists from The Scripps Research Institute and the Janssen Pharmaceutical Companies of Johnson & Johnson have found a way to induce antibodies to fight a wide range of influenza subtypes—work that could one day eliminate the need for repeated seasonal flu shots.

24 Aug 2015

Esperance, MD Anderson form strategic alliance to accelerate development of anti-cancer candidate EP-100

Esperance Pharmaceuticals Inc. today announced that it has entered into a strategic alliance agreement with MD Anderson Cancer Center to accelerate the clinical development of its lead anti-cancer candidate EP-100 for the treatment of ovarian cancer and to collaborate on preclinical studies of EP-100 as a treatment for breast cancer.

24 Aug 2015

European chestnut leaves contain ingredients with power to disarm deadly staph bacteria

Leaves of the European chestnut tree contain ingredients with the power to disarm dangerous staph bacteria without boosting its drug resistance, scientists have found.

24 Aug 2015

HPPI commences enrollment for Phase II(b) SCORING clinical trial for cancer treatment

HedgePath Pharmaceuticals, Inc., a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today enrollment has commenced in its Phase II(b) SCORING (SUBA-Cap Objective Response in Gorlin's) clinical trial.

23 Aug 2015

Berg and University of Miami extend partnership to battle cardiac dysfunction, heart failure

Berg, a Boston-based biopharmaceutical company, and the University of Miami Leonard M. Miller School of Medicine are extending its collaboration to battle cardiac dysfunction and heart failure. According to the American Heart Association, cardiovascular disease is the leading global cause of death, accounting for 17.3 million deaths per year, a number that is expected to grow to more than 23.6 million by 2030.

23 Aug 2015

IQWiG dossier assessment finds added benefit of afatinib in patients with certain mutations

Afatinib (trade name: Giotrif) has been approved since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI).

21 Aug 2015

Novel synthetic DNA vaccine induces protective immunity against MERS virus in animal study

A novel synthetic DNA vaccine can, for the first time, induce protective immunity against the Middle East Respiratory Syndrome (MERS) coronavirus in animal species, reported researchers from the Perelman School of Medicine at the University of Pennsylvania.

21 Aug 2015

Trojan horse strategy may elucidate why antibiotics ineffective in some patients

Bacteria are pretty wily creatures. Take for example, an organism such as Salmonella, which which are killed by antibiotics in lab tests, but can become highly resistant in the body.

21 Aug 2015

FDA accepts Allergan's resubmission of BOTOX sBLA for treatment of adults with upper limb spasticity

Allergan plc, a leading global pharmaceutical company today announced that the U.S. Food and Drug Administration has accepted the company's resubmission of its Supplemental Biologics License Application (sBLA) for BOTOX (onabotulinumtoxinA) for the treatment of adults with lower limb (involving ankle and toe muscles) spasticity in adults.

20 Aug 2015

60P to commence Phase II clinical trial among dengue fever patients

60 Degrees Pharmaceuticals, a company focused on development of therapeutics for tropical diseases, and Singapore General Hospital announced today that the Hospital has received a grant from Singapore's National Medical Research Council to support a Phase II clinical trial among dengue fever patients.

20 Aug 2015

PharmaMar to market and distribute APLIDIN drug candidate in Australia, New Zealand

PharmaMar has entered into an exclusive license and commercialization agreement with the pharmaceutical company Specialised Therapeutics Australia Pty (STA) to market and distribute the drug candidate APLIDIN (plitidepsin) in Australia and New Zealand.

20 Aug 2015

DelMar closes on $2.6 million registered direct placement

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced the closing of a registered direct placement (Placement) with $2.6 million received from the offering.

20 Aug 2015

Nuvo Research granted U.S. patent for novel topical foam formulations that use DMSO to enhance drug delivery

Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced that the United States Patent Office has granted U.S. patent no. 9,107,823 ('823 Patent) covering novel topical foam formulations that include dimethyl sulfoxide (DMSO) together with certain drug actives.

20 Aug 2015

Pharmaceuticals News and Research

Long lasting flu vaccine using antibodies advance from TSRI and Janssen

UH research points to promising target in treatment of pancreatic cancer

Clementia expands enrollment to include children with FOP in ongoing Phase 2 clinical trial

Lannett's net sales rise 23% to $99.3 million in fourth quarter fiscal 2015

MNX Global Logistics' new Life Sciences Logistics Centre opens in Amsterdam

Inovalon signs definitive agreement to acquire Avalere Health

Accutest makes strategic expansion into Latin America to support the growth of pharmaceutical sector

TSRI, Janssen collaborate to find universal flu vaccine

Esperance, MD Anderson form strategic alliance to accelerate development of anti-cancer candidate EP-100

European chestnut leaves contain ingredients with power to disarm deadly staph bacteria

HPPI commences enrollment for Phase II(b) SCORING clinical trial for cancer treatment

Berg and University of Miami extend partnership to battle cardiac dysfunction, heart failure

IQWiG dossier assessment finds added benefit of afatinib in patients with certain mutations

Novel synthetic DNA vaccine induces protective immunity against MERS virus in animal study

Trojan horse strategy may elucidate why antibiotics ineffective in some patients

FDA accepts Allergan's resubmission of BOTOX sBLA for treatment of adults with upper limb spasticity

60P to commence Phase II clinical trial among dengue fever patients

PharmaMar to market and distribute APLIDIN drug candidate in Australia, New Zealand

DelMar closes on $2.6 million registered direct placement

Nuvo Research granted U.S. patent for novel topical foam formulations that use DMSO to enhance drug delivery

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring